V9Z Share Price Performance
€0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
V9Z Community Narratives
There are no narratives available yet.
Recent V9Z News & Updates
Aceragen, Inc. Key Details
Last Reported Earnings
Mar 31, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.88
- Gross Margin
- -110.00%
- Net Profit Margin
- -559.86%
- Debt/Equity Ratio
- 1.3%
Aceragen, Inc. Competitors
Snowflake Analysis
About V9Z
- Founded
- 1989
- Employees
- 26
- CEO
- WebsiteView website
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
U.S. Market Performance
- 7 Days: 0.5%
- 3 Months: 11.7%
- 1 Year: 15.7%
- Year to Date: 10.1%
The market has been flat over the last week. More promisingly, the market is up 16% over the past year. Earnings are forecast to grow by 15% annually. Market details ›